96 related articles for article (PubMed ID: 12351610)
1. Cardiac dysfunction in clinical trials of trastuzumab.
Page E; Assouline D; Brun O; Coeffic D; Fric D; Winckel P
J Clin Oncol; 2002 Oct; 20(19):4119; author reply 4120. PubMed ID: 12351610
[No Abstract] [Full Text] [Related]
2. Cardiac dysfunction in the trastuzumab clinical trials experience.
Seidman A; Hudis C; Pierri MK; Shak S; Paton V; Ashby M; Murphy M; Stewart SJ; Keefe D
J Clin Oncol; 2002 Mar; 20(5):1215-21. PubMed ID: 11870163
[TBL] [Abstract][Full Text] [Related]
3. Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study.
Cortes J; Di Cosimo S; Climent MA; Cortés-Funes H; Lluch A; Gascón P; Mayordomo JI; Gil M; Benavides M; Cirera L; Ojeda B; Rodríguez CA; Trigo JM; Vazquez J; Regueiro P; Dorado JF; Baselga J;
Clin Cancer Res; 2009 Jan; 15(1):307-14. PubMed ID: 19118059
[TBL] [Abstract][Full Text] [Related]
4. 4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2/neu overexpressing advanced breast cancer: single institution prospective study.
Janku F; Pribylova O; Zimovjanova M; Pazdrova G; Safanda M; Zemanova M; Petruzelka L
Bull Cancer; 2004 Oct; 91(10):E279-83. PubMed ID: 15582895
[TBL] [Abstract][Full Text] [Related]
5. Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide.
Kelly H; Kimmick G; Dees EC; Collichio F; Gatti L; Sawyer L; Ivanova A; Dressler L; Graham ML; Carey LA
Clin Breast Cancer; 2006 Aug; 7(3):237-43. PubMed ID: 16942640
[TBL] [Abstract][Full Text] [Related]
6. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: preliminary results of a feasibility-phase II study aimed at cardiotoxicity.
Nisticò C; Bria E; Vaccaro V; Cuppone F; Fornier M; Sperduti I; Carpino A; Izzo F; Tropea F; Cognetti F; Terzoli E
Anticancer Drugs; 2009 Feb; 20(2):109-14. PubMed ID: 19209027
[TBL] [Abstract][Full Text] [Related]
8. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.
Perez EA; Suman VJ; Rowland KM; Ingle JN; Salim M; Loprinzi CL; Flynn PJ; Mailliard JA; Kardinal CG; Krook JE; Thrower AR; Visscher DW; Jenkins RB
Clin Breast Cancer; 2005 Dec; 6(5):425-32. PubMed ID: 16381626
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab cardiotoxicity: Speculations regarding pathophysiology and targets for further study.
Schneider JW; Chang AY; Garratt A
Semin Oncol; 2002 Jun; 29(3 Suppl 11):22-8. PubMed ID: 12138394
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer.
Mirtsching B; Cosgriff T; Harker G; Keaton M; Chidiac T; Min M
Clin Breast Cancer; 2011 Apr; 11(2):121-8. PubMed ID: 21569998
[TBL] [Abstract][Full Text] [Related]
11. Anhydramnios associated with administration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy.
Bader AA; Schlembach D; Tamussino KF; Pristauz G; Petru E
Lancet Oncol; 2007 Jan; 8(1):79-81. PubMed ID: 17196514
[No Abstract] [Full Text] [Related]
12. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.
Seidman AD; Berry D; Cirrincione C; Harris L; Muss H; Marcom PK; Gipson G; Burstein H; Lake D; Shapiro CL; Ungaro P; Norton L; Winer E; Hudis C
J Clin Oncol; 2008 Apr; 26(10):1642-9. PubMed ID: 18375893
[TBL] [Abstract][Full Text] [Related]
13. Impaired wound healing and bilateral mastectomy flap necrosis in a patient with locally advanced breast cancer after neoadjuvant Paclitaxel with bevacizumab.
Lazzati V; Zygoń J; Lohsiriwat V; Veronesi P; Petit JY
Aesthetic Plast Surg; 2010 Dec; 34(6):796-7. PubMed ID: 20567970
[No Abstract] [Full Text] [Related]
14. Cardiotoxicity concerns prompt data review in breast cancer trial.
Friedrich MJ
J Natl Cancer Inst; 2002 May; 94(9):650-1. PubMed ID: 11983752
[No Abstract] [Full Text] [Related]
15. Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide for operable HER2-positive breast cancer.
Ferretti G; Felici A; Papaldo P; Carlini P; Fabi A; Cognetti F
Oncologist; 2006 May; 11(5):533; author reply 534. PubMed ID: 16720857
[No Abstract] [Full Text] [Related]
16. Cutaneous photosensitivity induced by paclitaxel and trastuzumab therapy associated with aberrations in the biosynthesis of porphyrins.
Cohen AD; Mermershtain W; Geffen DB; Schoenfeld N; Mamet R; Cagnano E; Cohen Y; Halevy S
J Dermatolog Treat; 2005 Feb; 16(1):19-21. PubMed ID: 15897162
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab-associated peripheral vascular toxicity.
Pansegrau GK; Grant DR; Norris B; Gelmon KA
J Clin Oncol; 2007 Apr; 25(11):1438-40. PubMed ID: 17416865
[No Abstract] [Full Text] [Related]
18. Fatal hemoptysis in a patient with breast cancer treated with bevacizumab and paclitaxel.
Philippin-Lauridant G; Thureau S; Ouvrier MJ; Blot E
Ann Oncol; 2008 Nov; 19(11):1977-8. PubMed ID: 18801882
[No Abstract] [Full Text] [Related]
19. Dose-dense chemotherapy with trastuzumab is an appropriate option.
Dang C; Norton L; Hudis C
J Clin Oncol; 2008 Jul; 26(21):3655-6; author reply 3656. PubMed ID: 18640949
[No Abstract] [Full Text] [Related]
20. [Paclitaxel for treatment of advanced breast cancers].
Ito Y
Nihon Rinsho; 2000 Apr; 58 Suppl():259-64. PubMed ID: 11026004
[No Abstract] [Full Text] [Related]
[Next] [New Search]
